Charles River Laboratories International, Inc. Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

CRL

주식 순위 #1504
Charles River Laboratories International, Inc. operates as a contract research... Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
주가
$300.30
마지막 동기화: 2026-10-16
시가총액
$14.46B
변동 (1일)
-1.89%
변동 (1년)
68.22%
국가
US
거래 Charles River Laboratories International, Inc. (CRL)

카테고리

Healthcare
Charles River Laboratories International, Inc. (CRL)의 영업이익률
October 2026 기준 영업이익률 TTM: 12.35%
Charles River Laboratories International, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 12.35%입니다. 2023년 말 기준 영업이익률은 14.95%였습니다.
Charles River Laboratories International, Inc.의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
연도 영업이익률 변화
2026 (TTM) 12.35% 120.14%
2024 5.61% -62.47%
2023 14.95% -8.67%
2022 16.37% -1.74%
2021 16.66% 12.57%
2020 14.80% 10.45%
2019 13.40% -8.34%
2018 14.62% -5.80%
2017 15.52% 9.84%
2016 14.13% -6.67%
2015 15.14% 10.59%
2014 13.69% 5.39%
2013 12.99% -11.51%
2012 14.68% -3.74%
2011 15.25% -157.90%
2010 -26.34% -286.81%
2009 14.10% -142.11%
2008 -33.48% -281.37%
2007 18.46% 3.82%
2006 17.78% 8.02%
2005 16.46% -20.10%
2004 20.60% -8.77%
2003 22.58% 2.45%
2002 22.04% 13.67%
2001 19.39% -8.62%
2000 21.22% 0.00%
유사 기업 또는 경쟁사의 영업이익률
회사 영업이익률 영업이익률 차이 국가
17.97% -98.54%
US
20.42% -98.35%
US
-10.70% -100.87%
US
0.00% -
CN
22.23% -98.20%
US
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.